pentostatin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
enzyme inhibitors 2098 53910-25-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pentostatin
  • deoxycoformycin
  • NSC218321
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
  • Molecular weight: 268.27
  • Formula: C11H16N4O4
  • CLOGP: -1.96
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 112.13
  • ALOGS: -1.40
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.25 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.59 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.63 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.96 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 11, 1991 FDA HOSPIRA INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
MeSH PA D058892 Adenosine Deaminase Inhibitors
FDA MoA N0000000233 Nucleic Acid Synthesis Inhibitors
FDA EPC N0000175595 Nucleoside Metabolic Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hairy cell leukemia indication 118613001
Chronic lymphoid leukemia, disease off-label use 92814006
Pulmonary edema contraindication 19242006 DOID:11396
Infectious disease contraindication 40733004
Low blood pressure contraindication 45007003
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
CNS Toxicity contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.02 acidic
pKa2 13.08 acidic
pKa3 13.73 acidic
pKa4 5.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Adenosine deaminase Enzyme INHIBITOR IC50 10.80 IUPHAR CHEMBL
Adenosine deaminase Enzyme Ki 11 CHEMBL

External reference:

IDSource
4020329 VUID
N0000148177 NUI
C0030896 UMLSCUI
D00155 KEGG_DRUG
395575MZO7 UNII
4355 INN_ID
28149003 SNOMEDCT_US
4020329 VANDF
8011 RXNORM
387154004 SNOMEDCT_US
5256 MMSL
d01356 MMSL
118563 MMSL
003617 NDDF
DB00552 DRUGBANK_ID
CHEMBL1580 ChEMBL_ID
439693 PUBCHEM_CID
D015649 MESH_DESCRIPTOR_UI
4805 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nipent HUMAN PRESCRIPTION DRUG LABEL 1 0409-0801 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 mg INTRAVENOUS NDA 15 sections